• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway.

作者信息

Ahmad S M, Larsen S K, Svane I M, Andersen M H

机构信息

Center for Cancer Immune Therapy (CCIT), Department of Hematology and Oncology, Copenhagen University Hospital, Herlev, Denmark.

出版信息

Leukemia. 2014 Jan;28(1):236-8. doi: 10.1038/leu.2013.261. Epub 2013 Sep 12.

DOI:10.1038/leu.2013.261
PMID:24091833
Abstract
摘要

相似文献

1
Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway.利用PD-L1特异性细胞毒性T细胞进行抗白血病免疫治疗，以对抗由PD-1途径介导的免疫逃逸机制。
Leukemia. 2014 Jan;28(1):236-8. doi: 10.1038/leu.2013.261. Epub 2013 Sep 12.
2
The stimulation of PD-L1-specific cytotoxic T lymphocytes can both directly and indirectly enhance antileukemic immunity.对程序性死亡配体1（PD-L1）特异性细胞毒性T淋巴细胞的刺激可直接和间接增强抗白血病免疫。
Blood Cancer J. 2014 Jul 18;4(7):e230. doi: 10.1038/bcj.2014.50.
3
In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors.在急性髓细胞白血病中，B7-H1（PD-L1）通过 TLR 配体和干扰素-γ诱导白血病细胞免受细胞毒性 T 细胞的杀伤，并可使用 MEK 抑制剂逆转。
Cancer Immunol Immunother. 2010 Dec;59(12):1839-49. doi: 10.1007/s00262-010-0909-y. Epub 2010 Sep 4.
4
Effect of TLR4 and B7-H1 on immune escape of urothelial bladder cancer and its clinical significance.TLR4和B7-H1对膀胱尿路上皮癌免疫逃逸的影响及其临床意义
Asian Pac J Cancer Prev. 2014;15(3):1321-6. doi: 10.7314/apjcp.2014.15.3.1321.
5
Tumor Escape Phenotype in Bladder Cancer Is Associated with Loss of HLA Class I Expression, T-Cell Exclusion and Stromal Changes.膀胱癌中的肿瘤逃逸表型与 HLA Ⅰ类分子表达缺失、T 细胞排除和基质改变有关。
Int J Mol Sci. 2021 Jul 6;22(14):7248. doi: 10.3390/ijms22147248.
6
Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.抗原呈递细胞上的程序性死亡配体1促进抗原特异性细胞毒性T淋巴细胞的诱导：在过继性T细胞免疫治疗中的应用。
J Immunother. 2016 Oct;39(8):306-15. doi: 10.1097/CJI.0000000000000136.
7
PD-1 /PD-L1 checkpoint in hematological malignancies.血液系统恶性肿瘤中的PD-1/PD-L1免疫检查点
Leuk Res. 2018 Apr;67:45-55. doi: 10.1016/j.leukres.2018.01.014. Epub 2018 Jan 31.
8
A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells.缺氧介导的癌细胞适应性免疫逃逸机制。
Cancer Res. 2014 Feb 1;74(3):665-74. doi: 10.1158/0008-5472.CAN-13-0992. Epub 2013 Dec 13.
9
Exosomal PD-L1: Roles in Tumor Progression and Immunotherapy.外泌体 PD-L1：在肿瘤进展和免疫治疗中的作用。
Trends Cancer. 2020 Jul;6(7):550-558. doi: 10.1016/j.trecan.2020.03.002. Epub 2020 Mar 29.
10
A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.一种TLR3特异性佐剂可缓解肿瘤疫苗免疫治疗中对PD-L1阻断的固有抗性，且无细胞因子毒性。
Cell Rep. 2017 May 30;19(9):1874-1887. doi: 10.1016/j.celrep.2017.05.015.

引用本文的文献

1
Arginase-1-specific T cells target and modulate tumor-associated macrophages.精氨酸酶-1特异性T细胞靶向并调节肿瘤相关巨噬细胞。
J Immunother Cancer. 2025 Jan 29;13(1):e009930. doi: 10.1136/jitc-2024-009930.
2
An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma.一种含有程序性死亡配体1（PD-L1）和程序性死亡配体2（PD-L2）肽段的具有免疫原性的首次人体免疫调节疫苗在滤泡性淋巴瘤中是可行的，并显示出早期疗效迹象。
Oncoimmunology. 2021 Sep 25;10(1):1975889. doi: 10.1080/2162402X.2021.1975889. eCollection 2021.
3
Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy.

本文引用的文献

1
PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.PD-L1 表达是侵袭性 B 细胞淋巴瘤和病毒相关性恶性肿瘤的一个亚群的特征。
Clin Cancer Res. 2013 Jul 1;19(13):3462-73. doi: 10.1158/1078-0432.CCR-13-0855. Epub 2013 May 14.
2
Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells.皮肤T细胞淋巴瘤细胞是免疫检查点配体PD-L1特异性细胞毒性T细胞的靶标。
Leukemia. 2013 Nov;27(11):2251-3. doi: 10.1038/leu.2013.118. Epub 2013 Apr 18.
3
HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients.
在接受检查点抑制剂联合放疗的胰腺癌患者中，预先存在的 TGF-β 特异性 T 细胞免疫预测生存。
J Immunother Cancer. 2023 Mar;11(3). doi: 10.1136/jitc-2022-006432.
4
An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial.基于精氨酸酶 1 和 PD-L1 衍生肽的疫苗治疗骨髓增殖性肿瘤：首例人体临床试验。
Front Immunol. 2023 Feb 23;14:1117466. doi: 10.3389/fimmu.2023.1117466. eCollection 2023.
5
Tumor microenvironment antigens.肿瘤微环境抗原。
Semin Immunopathol. 2023 Mar;45(2):253-264. doi: 10.1007/s00281-022-00966-0. Epub 2022 Sep 29.
6
A Novel Therapeutic Tumor Vaccine Targeting MUC1 in Combination with PD-L1 Elicits Specific Anti-Tumor Immunity in Mice.一种靶向MUC1并与PD-L1联合使用的新型治疗性肿瘤疫苗在小鼠体内引发特异性抗肿瘤免疫。
Vaccines (Basel). 2022 Jul 8;10(7):1092. doi: 10.3390/vaccines10071092.
7
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.一项针对 IDO/PD-L1 免疫调节疫苗联合纳武利尤单抗治疗转移性黑色素瘤的 1/2 期临床试验。
Nat Med. 2021 Dec;27(12):2212-2223. doi: 10.1038/s41591-021-01544-x. Epub 2021 Dec 9.
8
Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A Phase IIa Study.使用IO103（一种用于基底细胞癌的新型免疫调节疫苗）进行程序性死亡配体1（PD-L1）疫苗接种：一项IIa期研究。
Cancers (Basel). 2021 Feb 22;13(4):911. doi: 10.3390/cancers13040911.
9
Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial.针对 PD-L1 的肽疫苗 IO103 在多发性骨髓瘤中的应用：一项 I 期首次人体试验的新型免疫调节疫苗。
Front Immunol. 2020 Nov 9;11:595035. doi: 10.3389/fimmu.2020.595035. eCollection 2020.
10
A Novel Anti-PD-L1 Vaccine for Cancer Immunotherapy and Immunoprevention.一种用于癌症免疫治疗和免疫预防的新型抗PD-L1疫苗。
Cancers (Basel). 2019 Dec 1;11(12):1909. doi: 10.3390/cancers11121909.
在癌症患者中，高频率出现针对免疫检查点配体 PD-L1 的 HLA 限制 CTL。
Cancer Res. 2013 Mar 15;73(6):1764-76. doi: 10.1158/0008-5472.CAN-12-3507. Epub 2013 Jan 17.
4
The role of B7 family molecules in hematologic malignancy.B7 家族分子在血液恶性肿瘤中的作用。
Blood. 2013 Jan 31;121(5):734-44. doi: 10.1182/blood-2012-10-385591. Epub 2012 Dec 6.
5
Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma.骨髓基质细胞诱导骨髓瘤细胞表达 B7-H1，从而在多发性骨髓瘤中产生侵袭性特征。
Leukemia. 2013 Feb;27(2):464-72. doi: 10.1038/leu.2012.213. Epub 2012 Jul 25.
6
The blockade of immune checkpoints in cancer immunotherapy.癌症免疫疗法中的免疫检查点阻断。
Nat Rev Cancer. 2012 Mar 22;12(4):252-64. doi: 10.1038/nrc3239.
7
Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells.滤泡性淋巴瘤肿瘤内滤泡辅助 T 细胞的特征：恶性 B 细胞存活中的作用。
Leukemia. 2012 May;26(5):1053-63. doi: 10.1038/leu.2011.301. Epub 2011 Oct 21.
8
Regulatory T cells and immunodeficiency in mycosis fungoides and Sézary syndrome.调节性 T 细胞与蕈样肉芽肿和赛泽里综合征中的免疫缺陷。
Leukemia. 2012 Mar;26(3):424-32. doi: 10.1038/leu.2011.237. Epub 2011 Sep 9.
9
Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma.基于单克隆抗体的治疗作为多发性骨髓瘤的一种新的治疗策略。
Leukemia. 2012 Feb;26(2):199-213. doi: 10.1038/leu.2011.214. Epub 2011 Aug 19.
10
Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation.降低强度预处理异基因造血干细胞移植后 EBV 再激活的特点。
Leukemia. 2011 Jun;25(6):932-8. doi: 10.1038/leu.2011.26. Epub 2011 Feb 25.